Pharma Mar SA
Christophe Chevreau has a diverse work experience in the pharmaceutical industry. Christophe worked at PharmaMar as both an Associate Director of Business Development and a Business Development Manager. Christophe was responsible for managing the launch of the company's first drug, Yondelis, in various territories and presenting it to healthcare professionals. Christophe also worked at Quintiles as a Regional Unit Head, overseeing the launch of Savene in Spain and promoting it to oncologists and hematologists. Prior to that, Christophe worked at NUCLIBER, S.A. as a Jefe de Ventas, where they prepared marketing plans, managed sales teams, and negotiated licensing deals.
Christophe Chevreau earned a Master's degree in Operations and Production Management from the Institute of Business Administration in Caen, France in 1997. Prior to that, they obtained a Master's degree in Industrial Economy, specifically Master of Economic Sciences, from the University of Caen in France, between 1991 and 1996.
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.